Phase I Trial of Oral PX-866

PHASE1CompletedINTERVENTIONAL
Enrollment

90

Participants

Timeline

Start Date

June 30, 2008

Primary Completion Date

September 30, 2011

Study Completion Date

September 30, 2011

Conditions
Advanced Solid Tumors
Interventions
DRUG

PX-866

Oral solution, dose escalation, once per day on days 1 to 5 and 8 to 12 or days 1-28 of a 28 day cycle, until progression or development of unacceptable toxicity

Trial Locations (2)

77030

M.D. Anderson Cancer Center, Houston

80045

University of Colorado Health Sciences Center, Aurora

Sponsors
All Listed Sponsors
lead

Cascadian Therapeutics Inc.

INDUSTRY

NCT00726583 - Phase I Trial of Oral PX-866 | Biotech Hunter | Biotech Hunter